Short Interest in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Grows By 41.6%

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 8,610,000 shares, an increase of 41.6% from the October 15th total of 6,080,000 shares. Based on an average trading volume of 535,900 shares, the short-interest ratio is currently 16.1 days.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new position in SELLAS Life Sciences Group during the second quarter worth about $39,000. XTX Topco Ltd acquired a new position in shares of SELLAS Life Sciences Group in the 3rd quarter worth approximately $78,000. State Street Corp raised its holdings in shares of SELLAS Life Sciences Group by 30.2% in the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after buying an additional 40,500 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of SELLAS Life Sciences Group by 17.1% during the 3rd quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock worth $757,000 after buying an additional 88,183 shares during the period. Finally, Anson Funds Management LP acquired a new stake in SELLAS Life Sciences Group in the 3rd quarter valued at $992,000. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Price Performance

Shares of NASDAQ SLS traded up $0.05 during trading hours on Friday, reaching $1.32. The stock had a trading volume of 861,803 shares, compared to its average volume of 1,071,800. The company has a market cap of $84.92 million, a price-to-earnings ratio of -1.91 and a beta of 2.39. SELLAS Life Sciences Group has a twelve month low of $0.50 and a twelve month high of $1.72. The business’s fifty day moving average is $1.23 and its two-hundred day moving average is $1.26.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Sell-side analysts forecast that SELLAS Life Sciences Group will post -0.55 earnings per share for the current fiscal year.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.